{
    "clinical_study": {
        "@rank": "52086", 
        "arm_group": [
            {
                "arm_group_label": "[14C] TH-302 (Label 1)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "[14C] TH-302 (Label 2)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, Phase 1, two-center trial to evaluate the mass balance and metabolite\n      profile of carbon 14 [14C]-labeled TH-302 (Label 1 and Label 2) followed by subsequent\n      treatment with unlabeled TH-302 in cancer subjects with locally advanced or metastatic solid\n      tumors."
        }, 
        "brief_title": "A Phase 1 TH-302 Mass Balance Trial", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subject with pathologically or cytologically confirmed solid tumor which is\n             locally advanced or metastatic, and either refractory to the standard therapy or for\n             which no effective standard therapy is available\n\n          -  Subject has measurable and evaluable disease as RECIST version 1.1\n\n          -  Age greater than or equal to (>=) 18 years and less than or equal to (=<) 70 years\n\n          -  Body mass index (BMI) >= 19 and =< 33 kilogram per square meter (kg/m^2), body weight\n             greater than (>) 50 kilogram (kg)\n\n          -  Eastern cooperative oncology group (ECOG) performance status of 0 to 1\n\n          -  Life expectancy of at least 3 months\n\n          -  At least 4 weeks from previous cytotoxic chemotherapy or radiation therapy and at\n             least 5 half-lives or 6 weeks, whichever is longer, after targeted or biologic\n             therapy\n\n          -  Acceptable renal function, liver function and hematologic status as defined in the\n             protocol\n\n          -  Other protocol-defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  New York Heart Association (NYHA) Class 3 or 4 congestive heart disease, myocardial\n             infarction within 6 months, unstable arrhythmia, symptomatic ischemic heart disease\n             or symptomatic peripheral arterial vascular disease\n\n          -  Severe chronic obstructive or other pulmonary disease with hypoxemia as defined in\n             the protocol\n\n          -  Major surgery, other than diagnostic surgery, =< 28 days prior to Day 1. Subject must\n             have completely recovered from surgery\n\n          -  Primary brain tumors or clinical evidence of active brain metastasis as defined in\n             the protocol\n\n          -  Treatment with strong inhibitors and/or inducers of drug metabolic enzymes or drug\n             transporter as defined in the protocol\n\n          -  Participation in a drug trial within 30 days prior to start of trial medication.\n             Participation in a trial involving administration of 14C-labeled compound(s) within\n             last 6 months prior to start of study drug\n\n          -  Inability to understand the protocol requirements, instructions and trial-related\n             restrictions, the nature, scope, and possible consequences of the trial\n\n          -  Legal incapacity or limited legal capacity\n\n          -  Other protocol-defined exclusion criteria could apply"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076230", 
            "org_study_id": "200592-007", 
            "secondary_id": "2013-003950-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "[14C] TH-302 (Label 1)", 
                "description": "[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.", 
                "intervention_name": "[14C] TH-302 (Label 1)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "[14C] TH-302 (Label 2)", 
                "description": "[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.", 
                "intervention_name": "[14C] TH-302 (Label 2)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "[14C] TH-302 (Label 1)", 
                    "[14C] TH-302 (Label 2)"
                ], 
                "description": "Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.", 
                "intervention_name": "Unlabeled TH-302", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "14C-TH-302", 
            "Advanced or Metastatic Solid Tumors"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49 6151 72 5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center located in"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Open-Label, Two-Center Trial to Investigate the Mass Balance and Metabolite Profile of TH-302 in Cancer Patients With Locally Advanced or Metastatic Solid Tumors", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics profile in plasma: Cmax, Tmax, AUC (0-t), lambda_z, t1/2, AUC (0-infinity), CL, Vss, Vz, MRT  for TH-302 and its active metabolite Br-IPM", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 8 of Cycle 1"
            }, 
            {
                "measure": "Pharmacokinetics profile in excreta: Cumulative Ae (0-t), Ae (0-infinity), percent radioactive dose excreted in urine and feces, AeUF, CLR, CLNR  for TH-302 and its active metabolite Br-IPM", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076230"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with Treatment-emergent adverse events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 30 after the last dose of study treatment"
            }, 
            {
                "measure": "Blood to plasma ratio of total 14C-radioactivity", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 8 of Cycle 1"
            }, 
            {
                "measure": "Total and free plasma concentrations of TH-302 in plasma", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }, 
            {
                "description": "Tumor response was defined as the occurrence of complete response (CR) or partial response (PR) based on the investigator's assessment according to RECIST v 1.1.", 
                "measure": "Number of subjects with tumor response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Unbound fraction (fu) of TH-302 in plasma", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "collaborator": {
                "agency": "Threshold Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}